initial public offerings (IPOs) trading on American exchanges

Thursday, March 27, 2014

Applied Genetic Technologies (AGTC) began trading on the NASDAQ on 27 March 2014


Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis, an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia, an inherited condition that is associated with color blindness, visual acuity loss, and extreme light sensitivity resulting in daytime blindness.


Suite D, 11801 Research Drive
United States

Key stats and ratios

Q4 (Dec '13)2013
Net profit margin-142.72%-529.72%
Operating margin-564.08%-381.53%
EBITD margin--351.27%
Return on average assets-10.64%-35.25%
Return on average equity--

No comments:

Post a Comment